{"denoms":[{"counts":[{"groupId":"BG000","value":"197"},{"groupId":"BG001","value":"395"},{"groupId":"BG002","value":"592"}],"units":"Participants"}],"groups":[{"description":"Participants randomized to receive their stable dose of commercial MTX (between 15-25 mg/week) and placebo IV infusions at Weeks 0, 4, 12, 16, and 20. Participants will be crossed over to Golimumab 2 mg/kg at Week 24, and receive administrations at Weeks 24, 28 and q8 weeks thereafter up to Week 100. Subjects randomized to Group I (Placebo + MTX) will have the opportunity to enter early escape at Week 16 and initiate Golimumab 2 mg/kg infusions (Weeks 16, 20, and q8 weeks up to Week 100) if they demonstrate a \\< 10% improvement in both tender and swollen joint count.","id":"BG000","title":"Group I: Placebo + Methotrexate (MTX)"},{"description":"Participants randomized to receive 2 mg/kg of Golimumab intravenously at Weeks 0, 4, and q8 weeks up to Week 100. Participants will be maintained on their stable dose of commercial MTX (between 15 and 25 mg/week) throughout the study. Participants will receive a placebo infusion at Week 16 and Week 24 to maintain the blind.","id":"BG001","title":"Group II: Golimumab 2 mg/kg + Methotrexate (MTX)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"11.26","value":"51.4"},{"groupId":"BG001","spread":"12.55","value":"51.9"},{"groupId":"BG002","spread":"12.13","value":"51.8"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"157"},{"groupId":"BG001","value":"326"},{"groupId":"BG002","value":"483"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"69"},{"groupId":"BG002","value":"109"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"82"}]}],"title":"Argentina"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"9"}]}],"title":"Australia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"37"}]}],"title":"Columbia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"31"}]}],"title":"Hungary"},{"categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"16"}]}],"title":"Korea, Republic of"},{"categories":[{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"64"}]}],"title":"Lithuania"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"26"}]}],"title":"Malaysia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"38"}]}],"title":"Mexico"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"6"}]}],"title":"New Zealand"},{"categories":[{"measurements":[{"groupId":"BG000","value":"36"},{"groupId":"BG001","value":"65"},{"groupId":"BG002","value":"101"}]}],"title":"Poland"},{"categories":[{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"46"},{"groupId":"BG002","value":"69"}]}],"title":"Russian Federation"},{"categories":[{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"58"},{"groupId":"BG002","value":"90"}]}],"title":"Ukraine"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"23"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}